Metformin Does Not Reduce Seizures in Active Epilepsy Patients

Source: Naunyn-Schmiedeberg's archives of pharmacology

Summary

This study looked at the effects of adding metformin, a medication commonly used for diabetes, to standard anti-seizure treatments in people with active epilepsy. Researchers conducted a trial with 60 participants, who were randomly assigned to receive either metformin or a placebo (a pill with no active ingredients) for six months. The main goal was to see if metformin could reduce the number of seizures, while also examining other health aspects like quality of life and safety.

The results showed that there was no significant difference in seizure frequency between the group taking metformin and the group taking the placebo. However, those taking metformin reported improvements in their quality of life compared to those on the placebo. Interestingly, the placebo group experienced increases in body mass index (BMI) and fat percentage, while the metformin group did not show these changes. Both groups were found to be safe, but the metformin group had fewer reported side effects.

These findings are important because they suggest that while metformin may not help reduce seizures, it could improve quality of life for some people with epilepsy. However, the study had limitations, such as a small number of participants and a short duration. More research with larger groups and longer treatment periods is needed to better understand the potential benefits and risks of using metformin alongside anti-seizure medications.

Original source